Latest News

Investors love accelerating growth.

Beverage company Zevia (NYSE:ZVIA) announced better-than-expected revenue in Q3 2026, with revenue up 18.4% year on year to $48.34 million. Guidance for next...

Admitted carriers moving into specialty lines are pressuring organic growth, even as integration gains and AI deployment support long-term expansion.

Refinancing debt at lower rates while shifting capital to high-growth markets sets up durable earnings growth without balance sheet strain.

On Nov. 4, 2026, Oracle shares slid in premarket trading as reports of a scrapped Tencent deal renewed focus on how it funds its AI buildout.

A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.

AI is currently driving high growth in the tech sector.

The "super intelligence" segment could be worth $11 trillion in several years.

Telecommunications infrastructure company Lumen Technologies (NYSE:LUMN) met Wall Street’s revenue expectations in Q3 2026, but revenue fell by 12.1% year on...

Figs barely made any news last month. Its stock jumped 53.8% anyway.

Liquified natural gas infrastructure provider Excelerate Energy (NYSE:EE) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 24...

AppLovin's ad platform added hundreds of millions in revenue last quarter at very little extra cost. Here's what drove the profit gain, where cash fell behind, and what the outlook implies.

Management outlines a bigger savings target and higher capital spending for a tough industrial market.

West Texas landowner Texas Pacific Land (NYSE:TPL) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 34.6% year on year to...

Greif (NYSE:GEF) reported higher fiscal 2026 earnings despite weak industrial demand and set a higher cost-savings target as it forecast further growth in adjusted EBITDA and free cash flow for fiscal 2027. Adjusted EBITDA rose nearly 12% to $625.7 million for fiscal 2026, while adjusted earnings p

Brookfield Renewable Partners (NYSE:BEP) reported record third-quarter funds from operations, as newly commissioned projects and gains from asset sales supported growth. The company also extended the voting deadline for its proposed corporate simplification after participation by unitholders fell sh

Claros Mortgage Trust (NYSE:CMTG) reported a third-quarter loss and said it plans to continue selling troubled loans and real estate assets while reducing debt, as elevated interest rates weigh on commercial real estate values. The company reported a GAAP net loss of $0.10 per share and a distribut

Brookfield Renewable (NYSE:BEPC) reported record third-quarter funds from operations as newly commissioned projects and asset sales helped lift results, while management said it expects full-year earnings growth to meet or exceed its long-term targets. The renewable power company generated funds fr

Viridian Therapeutics (NASDAQ:VRDN) reported $24.7 million in net product revenue from Lumvoa in the thyroid eye disease treatment’s first quarter on the market, with more than 100 patients having received at least one infusion by Sept. 30. President and CEO Steve Mahoney said the launch exceeded t

XPEL (NASDAQ:XPEL) reported higher third-quarter revenue and earnings as gross margin improved, but the company forecast a slowdown in fourth-quarter sales growth amid weakness in U.S. dealerships and the aftermarket. Revenue rose 9.9% to $137.8 million in the third quarter of 2026, while net incom

Adient (NYSE:ADNT) expects higher adjusted earnings in fiscal 2027 despite declining vehicle production and lower sales, as the automotive seating supplier relies on cost reductions and recoveries from customers to offset pressure from tariffs, commodities and changing vehicle mix. The company repo

Urogen Pharma (NASDAQ:URGN) reported third-quarter revenue of $89 million, more than triple the $27.5 million recorded a year earlier, as sales of bladder cancer treatment ZUSDURI continued to grow. The company said it expects to achieve profitability and generate positive cash flow in the fourth qu

United Therapeutics (NASDAQ:UTHR) reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inhaler to 2027. President and Chief Operating Officer Michael Benkowitz said the

Trinity Capital (NASDAQ:TRIN) reported third-quarter net investment income of $0.52 per share, covering its $0.51 quarterly distribution, as investment income and assets under management rose from a year earlier. The business development company generated $98 million in total investment income, up

Uranium assets reached $10 billion as management lifted the dividend 25%.